Innoviva, Inc. (INVA) - Deep Dive Research Report

Section 1: What the Company Does

Innoviva is a healthcare holding company that collects royalty checks from some of the world's best-selling respiratory inhalers while simultaneously building a commercial-stage hospital antibiotic business, funded in part by those royalties. It is not a drug developer in the traditional sense. It does not run clinical trials on behalf of its core assets - it owns financial rights to drugs that were discovered and developed years ago, and it uses the steady cash those royalties generate to buy, commercialize, and grow a specialty therapeutics platform.

The business has three distinct parts running simultaneously. First, it receives royalties - passive, recurring income - from GlaxoSmithKline on the sales of two globally distributed respiratory medicines, RELVAR/BREO ELLIPTA and ANORO ELLIPTA. These royalties require no sales force, no manufacturing, and no clinical spend. They arrive on a predictable schedule and generate substantial cash year after year. Second, through a subsidiary called Innoviva Specialty Therapeutics (IST), it actively commercializes four hospital-focused antibiotics and vasopressors in the U.S. market. These products treat conditions that kill people in ICUs and operating rooms - septic shock, drug-resistant pneumonia, complicated abdominal infections - and they are sold by a dedicated hospital sales force to infectious disease physicians and critical care specialists. Third, Innoviva deploys capital into a portfolio of early and growth-stage healthcare companies, taking equity stakes, providing convertible debt, and participating in venture rounds.

The company's history explains why this combination exists. Innoviva began life in 1996 as Advanced Medicine, Inc., became Theravance, Inc. in 1997, and spent the early 2000s as a clinical-stage respiratory drug developer working closely with GSK under a landmark Long-Acting Beta2 Agonist (LABA) Collaboration Agreement signed in 2002. That collaboration took GSK's inhaler platform and Theravance's small molecule chemistry and produced a family of once-daily inhaled treatments for COPD and asthma. The partnership was productive - BREO ELLIPTA was approved in 2013, ANORO ELLIPTA in 2013, and the triple combination TRELEGY ELLIPTA in 2017. But by 2013, management recognized that sitting on a royalty stream was fundamentally different from running a research organization, and the company restructured - splitting off the R&D operations into a separate entity called Theravance Biopharma (now listed on NASDAQ as TBPH), while the retained entity became a pure royalty manager. That entity rebranded as Innoviva, Inc. in 2016.

For several years after 2016, Innoviva was essentially a royalty vehicle. It owned participation rights in BREO and ANORO royalties and received substantial quarterly cash distributions. But management - particularly since CEO Pavel Raifeld took the helm - recognized that passive royalty management was a value-limiting strategy as the royalty assets aged. In 2022, the company executed two acquisitions in rapid succession that transformed its profile. In July 2022, it acquired Entasis Therapeutics for approximately $113 million, gaining an antibiotic called durlobactam in combination with sulbactam (which became XACDURO). One month later, in August 2022, it acquired La Jolla Pharmaceutical Company for approximately $149 million, gaining GIAPREZA (a vasopressor for septic shock) and XERAVA (an antibiotic for abdominal infections). These two acquisitions were integrated into a single commercial entity - Innoviva Specialty Therapeutics - which now operates as the growth engine of the group.

The central logic of the business model is capital recycling. Royalties from aging but still-growing respiratory inhalers provide roughly $250 million per year in high-margin, zero-effort cash. That cash is deployed into hospital antibiotics - a market that has historically been poorly commercialized because large pharma companies abandoned it in the 1990s and 2000s - and into a venture-style investment portfolio targeting healthcare innovation. The model only works if the royalties remain durable, the antibiotic commercial execution continues to improve, and the investment portfolio generates returns that justify the capital deployed.

A key structural point: Innoviva does not own the BREO or ANORO molecules and does not manufacture them. GSK does everything - R&D, manufacturing, global distribution, marketing. Innoviva receives a royalty check. This is why the royalty segment carries essentially no operating cost. All of Innoviva's operating leverage is in the IST segment, where building a hospital sales force, managing product launches, and contracting with GPOs (Group Purchasing Organizations) and hospital formularies is capital-intensive and operationally complex.

Section 2: Business Segments

2.1 Royalties Portfolio

The royalties business is the founding architecture of Innoviva. It generates income from two products: RELVAR ELLIPTA (branded as BREO ELLIPTA in the U.S.) and ANORO ELLIPTA, both marketed globally by GlaxoSmithKline.

BREO ELLIPTA is a once-daily inhaler combining fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta2 agonist) for the maintenance treatment of COPD and asthma. It was the first product from the GSK-Theravance LABA collaboration to reach the market, approved by the FDA in May 2013. ANORO ELLIPTA pairs umeclidinium bromide (a long-acting muscarinic antagonist) with vilanterol for once-daily COPD maintenance.

Innoviva's royalty rate on BREO/RELVAR is 15% of the first $3 billion of combined annual global net sales, stepping down to 5% on sales above that threshold. For ANORO, the royalty rate is upward-tiering from roughly 6.5% to 10% on annual global net sales. These are not trivial rates. The respiratory inhaler market for COPD and asthma is enormous, with BREO in particular benefiting from the global shift toward single-inhaler therapies and the ongoing expansion of COPD diagnosis rates in aging populations worldwide.

It is important to understand what Innoviva owns here and what it sold. In July 2022, simultaneously with the Entasis acquisition, Innoviva sold its 15% economic stake in Theravance Respiratory Company LLC (TRC) - which had been the vehicle through which Innoviva participated in TRELEGY ELLIPTA royalties - to Royalty Pharma for approximately $282 million in cash. This was a significant strategic decision: Innoviva monetized its participation in the third GSK respiratory product (TRELEGY), which was and remains the fastest-growing of the three ELLIPTA family products, in order to fund the IST acquisitions. The BREO and ANORO royalties were retained. This means Innoviva no longer participates in TRELEGY's growth, which is a relevant consideration when evaluating the trajectory of the royalties segment.

The royalties segment generated $250.3 million in FY 2025, very slightly down from $255.6 million in FY 2024. The mild softening reflects the maturity of the royalty-bearing products rather than any structural deterioration - BREO and ANORO are well past peak growth but have established significant installed bases among COPD patients who tend to stay on their inhalers long-term. This segment contributes essentially zero direct operating cost to Innoviva. It is the cash engine that funds everything else.

The competitive position of this segment is unique: there is no competition, because Innoviva owns a contractual right. The only risks are product decline (patients switching to TRELEGY or generic alternatives) and patent expiry. The ELLIPTA inhaler device patent is expected to run into the 2030s in the U.S., providing a protective runway, though the underlying chemical patents for vilanterol are older.

This segment represents approximately 61% of total FY 2025 revenue and is the primary source of cash generation for the group.

2.2 Innoviva Specialty Therapeutics (IST)

IST is the commercial and operational heart of Innoviva's growth strategy. It was assembled in 2022-2023 by combining the commercial operations of La Jolla Pharmaceutical and Entasis Therapeutics into a single hospital-focused therapeutics company. IST markets four commercialized products - GIAPREZA, XERAVA, XACDURO, and ZEVTERA - and owns the U.S. rights to a fifth, NUZOLVENCE, approved in December 2025 and planned for commercial launch in H2 2026.

IST's target market is the hospital - specifically the ICU, the surgical suite, and the infectious disease consultation service. These are among the most difficult selling environments in pharma: physicians are overworked, formulary access requires navigating hospital pharmacy & therapeutics (P&T) committees, and the products treat serious conditions where clinical urgency competes with institutional cost-containment pressure. But the market is also defensible: once a product makes it onto a hospital formulary and infectious disease physicians are trained on its use, switching costs are meaningful.

GIAPREZA (angiotensin II)

GIAPREZA was developed by La Jolla Pharmaceutical and FDA-approved in December 2017. It is an intravenous synthetic angiotensin II - a peptide hormone that constricts blood vessels and raises blood pressure by activating the renin-angiotensin-aldosterone system (RAAS). It is indicated to increase blood pressure in adults with septic shock or other distributive shock.

Septic shock is one of the leading causes of ICU death worldwide. The standard treatment protocol involves fluid resuscitation followed by vasopressors - drugs that constrict blood vessels to maintain blood pressure. The traditional vasopressors are norepinephrine (first-line per Surviving Sepsis Campaign guidelines), vasopressin, and epinephrine. GIAPREZA occupies a distinct clinical niche: it works through a completely different mechanism (RAAS activation) than catecholamines like norepinephrine, which means it can rescue patients who have become refractory to high-dose catecholamine therapy. When a patient in septic shock is on maximum doses of norepinephrine and still losing the pressure battle, GIAPREZA offers a physiologically distinct rescue option.

The clinical logic is powerful but adoption required building physician awareness of the RAAS mechanism in shock. La Jolla launched GIAPREZA in 2018 but struggled commercially - the company was under-resourced and could not build the hospital sales infrastructure needed to penetrate the ICU market. Innoviva's acquisition of La Jolla and subsequent integration into IST gave GIAPREZA access to a properly-funded commercial operation. GIAPREZA generated $53.4 million in FY 2024 and grew to $71.8 million in FY 2025 - real acceleration driven by IST's commercial build-out.

XERAVA (eravacycline)

XERAVA is a fully synthetic fluorocycline antibiotic of the tetracycline class, developed by Tetraphase Pharmaceuticals and FDA-approved in August 2018 for complicated intra-abdominal infections (cIAI) - things like peritonitis following bowel perforation, abscesses, appendicitis complications. It was originally part of Tetraphase's portfolio; La Jolla acquired XERAVA as part of a transaction before Innoviva's acquisition of La Jolla.

XERAVA's clinical utility lies in its broad-spectrum activity against gram-positive, gram-negative, and anaerobic bacteria including multi-drug-resistant strains. It demonstrated non-inferiority to ertapenem and meropenem in Phase 3 trials. The distinguishing feature versus tigecycline (a related tetracycline used in similar settings) is a more favorable tolerability profile and activity against tetracycline-resistant organisms.

XERAVA is the smallest and slowest-growing of IST's products. It generated $12.8 million in FY 2024 and $13.3 million in FY 2025 - marginal growth. The cIAI market is contested by generic carbapenems that are cheap and widely used, making XERAVA a niche player for resistant infections or specific clinical scenarios.

XACDURO (sulbactam for injection; durlobactam for injection)

XACDURO is a co-packaged intravenous antibiotic combination approved by the FDA in May 2023 specifically for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii-calcoaceticus complex. This is a critically important approval because Acinetobacter baumannii is among the most feared multi-drug-resistant (MDR) hospital pathogens - it is one of the WHO's critical priority pathogens and is notoriously difficult to treat.

The mechanism: sulbactam is an old beta-lactam antibiotic that has intrinsic activity against Acinetobacter. Durlobactam is a novel beta-lactamase inhibitor developed by Entasis Therapeutics specifically to protect sulbactam from the carbapenemase and other beta-lactamase enzymes that MDR Acinetobacter produces. Together, XACDURO restores sulbactam's killing activity against strains that would otherwise be resistant to it. The clinical development was done in collaboration with GARDP (the Global Antibiotic Research and Development Partnership).

XACDURO won clinical traction rapidly after approval. It was added to the 2024 IDSA (Infectious Diseases Society of America) treatment guidelines for Acinetobacter infections - the highest institutional endorsement possible in the infectious disease space. It was also nominated for the Prix Galien USA Best Biotechnology Product award in both 2024 and 2025. From $14.7 million in FY 2024, XACDURO grew to $33.4 million in FY 2025 - 127% growth, the fastest-growing product in the IST portfolio.

ZEVTERA (ceftobiprole)

ZEVTERA is an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica Ltd. (a Swiss specialty pharma company) under an exclusive U.S. distribution and licensing agreement signed in December 2024. The FDA approved ZEVTERA in April 2024, making it the first and only cephalosporin approved for Staphylococcus aureus bloodstream infections (bacteremia) including right-sided endocarditis caused by MRSA - the last new MRSA therapy approved for this indication since 2006. ZEVTERA is also approved for HABP and community-acquired bacterial pneumonia (CABP).

ZEVTERA's approval for MRSA bacteremia is particularly significant because the current standard of care is vancomycin (which requires monitoring for nephrotoxicity) and daptomycin (which cannot be used for pulmonary infections). In the Phase 3 ERADICATE trial, ceftobiprole achieved non-inferiority vs. daptomycin for MRSA bacteremia with a favorable tolerability profile. The commercial launch occurred in May 2025. ZEVTERA contributed minimal revenue in Q3 2025 ($0.1 million) given it had just launched, but the commercial trajectory is watched carefully as the primary IST growth driver in 2026.

NUZOLVENCE (zoliflodacin)

NUZOLVENCE received FDA approval in December 2025, making it the first new drug class for gonorrhea in decades. It is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor - a novel mechanism completely distinct from existing antibiotics. A single oral dose of NUZOLVENCE achieves a 90.9% microbiological cure rate against urogenital gonorrhea, demonstrated as non-inferior to the ceftriaxone plus azithromycin combination regimen in a Phase 3 trial of 930 participants.

Gonorrhea infects over 82 million people worldwide annually and is the second most reported bacterial STI in the United States. The public health urgency: ceftriaxone - the last reliable first-line treatment - is showing rising resistance globally, with WHO data showing resistance rates increasing from 0.8% to 5% between 2022 and 2024. Treatment failures have been confirmed across Asia, Europe, and Australia. NUZOLVENCE addresses this emerging gap.

NUZOLVENCE was co-developed with GARDP (Global Antibiotic Research and Development Partnership) and was developed specifically as a publicly-partnered, non-profit-aligned antibiotic for a disease disproportionately affecting lower-income populations. The commercialization strategy in H2 2026 is still being determined - Innoviva has stated it may partner with a larger organization or commercialize independently.

IST's combined U.S. net product sales grew from $80.9 million in FY 2024 to $119.2 million in FY 2025 (47% growth), with total global product sales of $172.1 million. Management has guided $150 million or more in U.S. net product sales for 2026.

2.3 Strategic Healthcare Investments

The third pillar is a portfolio of financial investments in early to mid-stage healthcare companies, held through various subsidiaries including the ISP Fund LP. At December 31, 2025, this portfolio was valued at approximately $614 million, making it a material component of Innoviva's balance sheet.

The single largest holding is Armata Pharmaceuticals, valued at approximately $397.9 million. Armata is a clinical-stage bacteriophage company - bacteriophages are viruses that selectively infect and kill bacteria, and Armata is developing them as treatments for drug-resistant bacterial infections that cannot be treated with conventional antibiotics. Innoviva has been a significant financial supporter of Armata, providing multiple rounds of equity and debt financing. Armata announced positive Phase 2 data in Staphylococcus aureus bacteremia in late 2025, which drove significant share price appreciation. If bacteriophage therapy achieves regulatory approval, Armata could become a major asset; if the clinical pathway stalls, this is a large concentrated bet that could reverse.

Beyond Armata, Innoviva has made investments in Gate Neurosciences (mental health therapeutics, $15 million convertible note in Q1 2025), Beacon Biosignals (AI-driven neurotechnology for neurological/psychiatric/sleep disorders, $17.5 million Series B in October 2025), Lyndra Therapeutics (ultra-long-acting oral drug delivery platform, $10.2 million in Q3 2025), Armata additional term loan ($15 million in Q3 2025), and through the ISP Fund LP a diversified set of healthcare equity positions. The ISP Fund accounted for $79.7 million at year-end 2025, and the remaining other investments totaled $136.4 million.

This segment does not generate recurring income in the traditional sense - its "returns" flow through as fair value changes in equity positions, interest income on term loans, and eventual realizations. The Armata stake has produced very large positive fair value adjustments as bacteriophage as a field has attracted growing investor attention. But fair value gains are not cash, and this portfolio represents real capital at risk.

Segment Comparison Summary

Segment	Core Activity	Revenue Type	FY 2025 Revenue	Growth	Strategic Role
Royalties	Royalty receipts from GSK on BREO/ANORO	Recurring royalties	~$250M	Slightly declining	Cash engine
IST	Hospital antibiotic/vasopressor commercialization	Product sales	~$172M	+77%	Growth driver
Investments	Equity/debt stakes in healthcare cos	Fair value + interest	~$614M portfolio value	+$161M FV gain	Capital appreciation option

Section 3: Products and Business Detail

Royalty Products (Managed by GSK)

BREO ELLIPTA / RELVAR ELLIPTA - The ELLIPTA inhaler device is GSK's proprietary dry powder inhaler platform. Inside: fluticasone furoate (ICS) and vilanterol (LABA). Approved in the U.S. in 2013 for COPD; the asthma indication followed. BREO is a once-daily prescription inhaler; the clinical advantage over twice-daily predecessors like Advair (salmeterol/fluticasone) is dosing convenience and vilanterol's 24-hour bronchodilation profile. BREO is marketed globally under the RELVAR name in many markets.

ANORO ELLIPTA - The ELLIPTA device again, this time with umeclidinium (LAMA) plus vilanterol (LABA). No corticosteroid. Approved in 2013 for COPD maintenance. Positioned for patients whose primary need is bronchodilation without corticosteroid exposure.

Innoviva receives royalties on these two products but plays no role in their manufacturing, marketing, distribution, or clinical development. GSK handles all of it across 100+ countries.

IST Products (Commercialized Directly)

GIAPREZA - Manufactured as an intravenous formulation of synthetic human angiotensin II (2.5 mcg/mL concentrate). It must be administered in an ICU setting with continuous hemodynamic monitoring. The drug is dosed by continuous IV infusion, titrated to blood pressure response. The manufacturing is relatively straightforward (synthetic peptide), but the supply chain is controlled to maintain sterility and potency in an IV formulation. GIAPREZA is marketed primarily in the U.S. through IST's hospital sales force. European marketing rights were authorized but commercial traction outside the U.S. remains limited.

XERAVA - Intravenous formulation of eravacycline dihydrochloride (50mg lyophilized powder per vial), reconstituted and infused over 60 minutes, twice daily. Requires IV infusion infrastructure standard in hospital settings. The novel tetracycline synthesis for XERAVA is proprietary but the manufacturing is standard IV antibiotic production. Marketed in the U.S.; limited ex-U.S. presence given La Jolla's historical resource constraints.

XACDURO - Co-packaged IV formulation: sulbactam sodium (vials) plus durlobactam sodium (vials), co-infused over 3 hours four times daily. The dosing regimen is complex (extended infusion), which requires patient and nurse education but also creates a clinical differentiation - extended infusions maximize time-above-minimum-inhibitory-concentration (a key pharmacokinetic driver for beta-lactam efficacy). U.S.-only commercialization by IST. Basilea Pharmaceutica held development rights; Entasis developed durlobactam in a global public-private partnership.

ZEVTERA - Intravenous ceftobiprole, provided as a 500mg powder vial, reconstituted and infused over 2 hours, three times daily. Licensed exclusively from Basilea, which has commercialized ZEVTERA in over 30 European and other international markets. Innoviva acquired U.S. rights in December 2024 and launched in May 2025. This is the only IST product where Innoviva is the U.S. commercialization partner of a product with an established international track record.

NUZOLVENCE - A 3g oral capsule of zoliflodacin, taken as a single dose. No IV required. This is the most commercially accessible of all IST products - it can be dispensed at a clinic, pharmacy, or urgent care center, which means the distribution model is fundamentally different from the hospital-focused model of the other four products. STI clinics, urgent care, primary care, and sexual health clinics are the distribution targets. The commercial launch is planned for H2 2026.

Manufacturing and Supply

Innoviva does not manufacture any of its commercial products. All manufacturing is outsourced to contract manufacturers and formulation facilities. This is consistent with the company's capital-light operating philosophy - the commercial investment is in sales force, medical affairs, and market access, not manufacturing assets. For ZEVTERA, Basilea handles manufacturing; for the La Jolla-derived products, existing CMO relationships were maintained post-acquisition.

Geographies

The royalties segment is truly global - BREO and ANORO are sold in the U.S., Europe, Japan, and across Asia Pacific. IST commercial operations are currently U.S.-focused, with limited international sales (primarily of XERAVA). FY 2025 international net product sales were approximately $52.9 million (total $172.1M minus U.S. $119.2M), which likely reflects XERAVA's ex-U.S. sales through licensing arrangements. The U.S. hospital market is IST's primary focus and commercial priority.

Section 4: Customers

Royalties Segment Customers

There is effectively one customer for the royalties business: GlaxoSmithKline. This is both the strength and the vulnerability of the segment. GSK pays royalties based on its own reported net sales figures for BREO and ANORO, audited under the collaboration agreement. Innoviva has no direct relationship with the end patient or even the prescribing physician - the royalty check comes from one counterparty.

GSK's interest is to maximize sales of BREO and ANORO in its own portfolio. However, GSK also owns TRELEGY (the triple combination successor product that Innoviva sold its stake in), which creates a degree of internal competition within GSK's respiratory portfolio. TRELEGY has been growing faster than BREO or ANORO, partly cannibalizing both. Innoviva is a passive recipient - it cannot influence GSK's promotional priorities.

IST Customers - Hospitals and ICUs

IST's customers are U.S. hospitals, specifically:

Infectious Disease Physicians - The primary clinical decision-maker for XACDURO, XERAVA, and ZEVTERA. Infectious disease consultants are called in for complex or drug-resistant infections. They know the guidelines, read the literature, and select antibiotics based on pathogen, susceptibility pattern, and patient profile. They have a higher tolerance for newer, specialized antibiotics than generalist prescribers.

Critical Care Physicians and Intensivists - Primary decision-makers for GIAPREZA. ICU physicians managing septic shock patients make vasopressor decisions based on hemodynamic response in real time. The sales interaction here is less about persuading a specific prescribing decision and more about ensuring the product is on formulary and that the ICU team is familiar with the RAAS pathway in shock management.

Hospital Pharmacy and Therapeutics (P&T) Committees - Before any product can be prescribed at a hospital, it needs formulary approval. P&T committees - comprising pharmacists, physicians, and administrators - evaluate clinical evidence, cost-effectiveness, and safety profiles. Getting onto a hospital formulary is the gating event for commercial success. Once on formulary, the product is available for any physician in the hospital to order. This creates a meaningful barrier to both entry and exit: adding a new antibiotic to formulary requires committee time and documentation; removing an established antibiotic from formulary requires evidence of a problem.

Group Purchasing Organizations (GPOs) - Large hospital systems and GPOs like Vizient, Premier, and HealthTrust negotiate pricing contracts with pharmaceutical companies. Achieving GPO contract status accelerates formulary adoption across member hospitals. IST's progress in penetrating GPO contracts has been a key driver of GIAPREZA's accelerating sales.

Switching costs are meaningful in the hospital antibiotic context. Once a hospital's infectious disease service has been trained on XACDURO protocols, has seen clinical outcomes, and has written XACDURO into internal resistance-management guidelines, switching to an alternative requires re-education, guideline revision, and a clinical reason to change. For GIAPREZA, the drug is used in the most acute, time-sensitive clinical situations - when an ICU physician reaches for GIAPREZA, the protocol is already established in their mind. Disrupting that requires a compelling alternative.

Concentration risk is present in the IST segment to the extent that hospital purchase decisions are increasingly concentrated in large health systems and GPOs. However, no single hospital or health system represents a dominant portion of IST revenue - the customer base is hundreds of hospitals nationally.

Section 5: Competitive Landscape

Royalties Segment Competition

There is no direct competition for Innoviva's royalty stream. The royalties are contractual rights under the 2002 LABA Collaboration Agreement. The only competitive threat is product competition - if BREO or ANORO lose market share to other inhaled therapies, Innoviva's royalties decline.

In the COPD inhaler market, the competitive set is:

TRELEGY ELLIPTA (GSK/Pfizer) - the triple-combination successor that Innoviva sold its stake in. TRELEGY has been growing strongly and is partly cannibalizing BREO and ANORO.
BEVESPI AEROSPHERE (AstraZeneca) and STIOLTO RESPIMAT (Boehringer/Pfizer) - dual bronchodilator competitors to ANORO.
WIXELA INHUB and generic fluticasone/salmeterol - generic Advair launched in 2019. Lower price competition at the ICS/LABA tier where BREO competes.
DUPIXENT (Sanofi/Regeneron) - increasingly relevant for severe asthma (biologic, different mechanism, not direct inhaler competition but addresses severe asthmatic patients who previously needed high-dose ICS/LABA).

Innoviva benefits but also suffers from being passive here. GSK's promotional decisions determine which of its own products grows fastest. TRELEGY's success is genuinely good for GSK but not for Innoviva.

IST - Vasopressor Competition (GIAPREZA)

In the vasopressor/septic shock market:

Norepinephrine - First-line vasopressor, available as an ultra-cheap generic. GIAPREZA cannot and does not compete head-to-head; it is positioned as adjunctive therapy in refractory shock.
Vasopressin (Vasostrict, various generics) - Second-line vasopressor, also generic. Same positioning logic.
Methylene Blue - Used in refractory shock, cheap, off-label. Some overlap with GIAPREZA's niche.
Selepressin (Ferring Pharmaceuticals) - A selective vasopressin receptor agonist that failed in Phase 3 for septic shock, removing a potential competitor.

GIAPREZA's competitive position: it is the only approved RAAS-targeted vasopressor. Its mechanism is unique. The competition is not from novel drugs but from clinical inertia and cheap generics. The commercial strategy is to establish GIAPREZA as the standard adjunct for high-dose catecholamine-dependent shock, a position supported by growing clinical evidence.

IST - Hospital Antibiotic Competition

For XACDURO (Acinetobacter pneumonia):

Polymyxins (colistin, polymyxin B) - Used as last-resort agents for XDR Acinetobacter. Associated with significant nephrotoxicity. XACDURO offers superior safety.
Ampicillin-sulbactam (generic) - Related to XACDURO's mechanism but without durlobactam's protection against beta-lactamase enzymes. Less effective against resistant strains.
Tigecycline - Broad-spectrum glycylcycline. Active against Acinetobacter. Off-label for pneumonia (FDA black box warning for higher mortality in pneumonia). XACDURO is approved and on-label for HABP/VABP.
No other targeted Acinetobacter HABP approval - XACDURO is the only drug specifically approved for HABP/VABP caused by Acinetobacter. This is a durable regulatory differentiation.

For ZEVTERA (MRSA bacteremia/pneumonia):

Vancomycin - The standard of care for MRSA, available as cheap generic. Requires therapeutic drug monitoring due to nephrotoxicity risk.
Daptomycin (Cubicin, generic) - Standard alternative for MRSA bacteremia. Cannot be used for pulmonary infections (inactivated by surfactant). This is ZEVTERA's key wedge - MRSA bacteremia with a pulmonary component.
Ceftaroline (Teflaro, Pfizer) - Another newer cephalosporin with MRSA activity. Approved for CABP and skin infections, not bacteremia.
Linezolid - Active against MRSA but bacteriostatic (doesn't kill) and oral-focused. Different clinical use.
ZEVTERA's differentiation: the only cephalosporin approved for MRSA bacteremia, active in the lung (unlike daptomycin), and with a well-established non-inferiority profile vs. daptomycin.

For XERAVA (cIAI):

Carbapenems (meropenem, ertapenem, imipenem) - Cheap, effective, widely used. XERAVA competes primarily for resistant organism infections or carbapenem-sparing strategies.
Piperacillin-tazobactam (Zosyn, generic) - Standard cIAI treatment. Very cheap.
Cefazolin/metronidazole - Standard community cIAI regimen.
XERAVA's niche: MDR gram-positive and gram-negative organisms, tetracycline-resistant strains, carbapenem-sparing clinical decisions.

For NUZOLVENCE (gonorrhea):

Ceftriaxone injection - The current first-line standard. Injectable, effectively free in public health contexts. NUZOLVENCE's advantage: oral single dose vs. injection.
Gepotidacin (GSK) - Another novel oral gonorrhea antibiotic approved simultaneously by the FDA in December 2025. NUZOLVENCE's direct competitive arrival is gepotidacin. Both were approved on the same day - a significant competitive dynamic that Innoviva must navigate.
Cefixime (oral cephalosporin) - Used in some markets but not recommended in the U.S. due to resistance concerns.

The simultaneous approval of gepotidacin (from GSK, a large pharma with significant commercial infrastructure) on the same day as NUZOLVENCE is a real competitive challenge. Innoviva will need a well-resourced commercialization strategy or a strong partner to compete.

Barriers to Entry in Hospital Antibiotics

The barriers are high but not insurmountable:

Clinical development of antibiotics targeting resistant organisms is expensive (~$1-2 billion for a new antibiotic) and time-consuming (10-15 years).
Regulatory approval requires demonstration of efficacy in seriously ill patients - trial design is complex.
Hospital formulary access requires a dedicated sales force and medical affairs organization with deep infectious disease expertise.
The WHO critical priority pathogen list (ESKAPE pathogens: Enterococcus, Staphylococcus aureus, Klebsiella, Acinetobacter, Pseudomonas, Enterobacter) creates validated demand drivers, but the market for each specific drug is small - hospital antibiotics are niche by design.
Pricing power: antibiotics are typically priced at a fraction of oncology biologics. High-value specialty antibiotics like XACDURO and ZEVTERA have premium pricing in the $1,000-$5,000 per course range, but volume is limited by the severity of target indications.

Section 6: Industry

Respiratory Royalties - COPD and Asthma

COPD affects approximately 384 million people worldwide and is the third-leading cause of death globally. Asthma affects an additional 300 million. The inhaled therapy market for these conditions is among the largest in pharmaceutical - the global COPD/asthma therapeutics market was valued at approximately $25 billion as of 2024.

The inhaled COPD market is in a structural transition. Single-inhaler triple therapy (ICS + LAMA + LABA, typified by TRELEGY) has become the preferred maintenance strategy for most moderate-to-severe COPD patients, gradually displacing dual-combination products like BREO and ANORO. This is a well-understood trend that represents the primary secular headwind for Innoviva's royalty segment.

Demand drivers for COPD products include: aging global populations, rising COPD diagnosis rates in Asia-Pacific and Latin America, and the ongoing shift from generic/cheap therapies to branded once-daily devices that improve adherence. Regulatory drivers: the FDA and EMA both push for device improvements in inhalation therapy, which benefits newer ELLIPTA-device products over older DPI and MDI formats.

Cyclicality: not meaningfully cyclical. COPD is a chronic condition requiring ongoing medication regardless of economic conditions.

Hospital Antibiotics - Critical Care and Infectious Disease

The global hospital infection therapeutics market was valued at approximately $10.5 billion in 2024 and is projected to grow at a CAGR of approximately 3.8-4.0% through 2033. The broader antibiotics market is larger but most of its value is in cheap generics.

The structural dynamic driving demand for premium hospital antibiotics is antimicrobial resistance (AMR). The WHO designates ESKAPE pathogens as critical or high priority threats requiring new therapies. By WHO estimates, AMR already kills 1.27 million people directly per year globally, a figure expected to reach 10 million annually by 2050 without intervention. This is not a niche market concern - it is a declared global public health emergency.

However, the commercial economics of antibiotic development are deeply problematic. Most large pharmaceutical companies exited antibiotic R&D in the 1990s because:

The drugs cure patients (unlike cancer drugs or chronic disease medications, they are not taken indefinitely)
High-value new antibiotics are deliberately rationed by stewardship programs (to prevent resistance development)
The development cost rivals oncology but the revenue profile is far lower

This market failure has prompted government intervention: the GAIN Act (2012) and PASTEUR Act proposals in the U.S. attempt to create pull incentives for antibiotic development. The FDA has granted multiple special designations (QIDP - Qualified Infectious Disease Product, Priority Review, Breakthrough Therapy) to novel antibiotics including XACDURO, ZEVTERA, and NUZOLVENCE. These designations provide 5-year market exclusivity extensions and faster FDA review timelines.

The global Acinetobacter pneumonia therapeutics market was valued at approximately $300-700 million in 2024, growing at 6.7% CAGR. The global sepsis treatment market is approximately $15 billion. The gonorrhea treatment market is smaller in dollar terms but affects 1.6 million Americans annually, with the CDC estimating over 800,000 new gonorrhea cases per year in the U.S.

Regulatory Environment for Hospital Antibiotics

IST products benefit from specific regulatory pathways:

QIDP designation: gives 5-year market exclusivity extension for certain antibiotics
Priority Review: FDA review in 6 months vs. 12 months standard
IDSA clinical guidelines: inclusion drives prescriber confidence and institutional adoption
Infectious Diseases Society of America (IDSA) and ASHP (American Society of Health-System Pharmacists) treatment guidelines are the clinical bible for hospital prescribers

Section 7: Growth Triggers

The following triggers are extracted directly from four earnings calls/releases (Q3 2024, Q4/FY 2024, Q1 2025, Q3 2025) and the Q4/FY 2025 press release. Each is cited to its source.

ZEVTERA U.S. commercial launch, targeting mid-2025 - Management confirmed the exclusive distribution and licensing agreement with Basilea (signed December 2024) and communicated that commercial availability was anticipated by mid-2025. "(Q4/FY 2024 concall, February 26, 2025)"

"We have expanded our commercial platform with the addition of ceftobiprole/ZEVTERA to our portfolio. We're excited to launch this product in the U.S. in mid-2025 as a new MRSA-focused hospital antibiotic."

Zoliflodacin NDA submission and FDA Priority Review approval - NDA submission was targeted for H1 2025. The FDA granted Priority Review and set a PDUFA date of December 15, 2025. "(Q3 2025 concall, November 5, 2025)"

"[Zoliflodacin] has a PDUFA date of December 15, 2025 - this is a first-in-class, single-dose oral antibiotic for gonorrhea, addressing a disease with growing global drug resistance."

NUZOLVENCE commercial launch planned H2 2026 - Following FDA approval of NUZOLVENCE in December 2025, management guided H2 2026 commercialization, noting they are evaluating whether to commercialize independently or with a partnership. "(Q4/FY 2025 press release, February 25, 2026)"
IST U.S. net product sales guidance >$100M for 2025 - Set at Q4/FY 2024 and ultimately exceeded ($119.2M U.S. net product sales delivered for FY 2025). "(Q4/FY 2024 concall, February 26, 2025)"
IST U.S. net product sales guidance >$150M for 2026 - Upgraded guidance, citing GIAPREZA growth momentum, XACDURO ramp, and ZEVTERA launch contribution. "(Q4/FY 2025 press release, February 25, 2026)"

"We anticipate $150 million or more in IST U.S. net product sales in 2026, supported by continued growth in GIAPREZA and XACDURO and the contribution of ZEVTERA."

XACDURO inclusion in 2024 IDSA guidelines - Management highlighted that XACDURO was added to the updated 2024 IDSA guidelines for Acinetobacter infections - a milestone that management said would accelerate formulary adoptions. "(Q4/FY 2024 concall, February 26, 2025)"
Third consecutive quarter of >50% U.S. IST revenue growth - Management noted this as a marker of sustainable commercial momentum, not a one-time event. "(Q3 2025 concall, November 5, 2025)"

"The royalties portfolio reaffirmed its resilience with 5% growth compared to last year, while IST delivered a third consecutive quarter of greater than 50% year-over-year U.S. sales growth."

$125M share repurchase program authorized - Announced in Q4 2025 as capital deployment signal. "(Q3 2025 concall, November 5, 2025 / Q4/FY 2025 press release)"
Armata Pharmaceuticals Phase 2 positive data in S. aureus bacteremia - Investment portfolio trigger: Armata's clinical data drove significant fair value appreciation and positions the Armata stake for a potential liquidity event. "(Q3 2025 concall, November 5, 2025)"
Lyndra drug delivery platform acquisition - IST acquired Lyndra's ultra-long-acting oral drug delivery technology for $10.2M, signaling a pipeline technology bet for future product applications. "(Q3 2025 concall, November 5, 2025)"

Trigger	Timeline	Concall Source	Status
ZEVTERA U.S. launch	Mid-2025	Q4/FY 2024, Feb 2025	Delivered (May 2025)
NDA for zoliflodacin	H1 2025 filing	Q4/FY 2024, Q1 2025	Delivered (FDA approved Dec 2025)
NUZOLVENCE launch	H2 2026	Q4/FY 2025, Feb 2026	Upcoming
IST U.S. sales >$100M	FY 2025	Q4/FY 2024, Feb 2025	Delivered ($119.2M)
IST U.S. sales >$150M	FY 2026	Q4/FY 2025, Feb 2026	Guidance
XACDURO IDSA guideline inclusion	2024	Q4/FY 2024, Feb 2025	Delivered
Armata Phase 2 data	Q3 2025	Q3 2025, Nov 2025	Delivered

Section 8: Key Risks

1. Royalty Decline from BREO/ANORO Maturation

The mechanism: TRELEGY ELLIPTA (the triple-combination successor) is growing faster than BREO and ANORO and is partially cannibalizing both. GSK has a financial incentive to promote TRELEGY - it is a higher-priced product and GSK receives all the revenue from it (Innoviva sold its TRELEGY stake). As TRELEGY adoption increases, particularly for moderate-to-severe COPD patients who are the same population BREO targets, BREO and ANORO prescriptions decline. Add to this the ELLIPTA device patent expiry in the 2030s, which could enable generic ELLIPTA-format products. The royalty segment generated $250M in FY 2025, down marginally from FY 2024. If this trend accelerates - say 5-10% annual decline rather than the current near-flat - it progressively compresses the cash engine that funds IST's commercial build and the investment portfolio.

Calibration: high-probability, moderate-impact risk. Not catastrophic but a multi-year headwind.

2. IST Commercial Execution and Hospital Sales Complexity

The mechanism: IST is building a hospital-focused commercial operation from scratch (2022 acquisitions). Hospital selling is fundamentally different from primary care - it requires deep clinical relationships with infectious disease specialists, formulary navigation at hospital P&T committees, and engagement with GPOs. Building this infrastructure is expensive and takes time. If the sales force underperforms - due to turnover, formulary losses, or physician preference shifts - the growth trajectory of GIAPREZA, XACDURO, and ZEVTERA disappoints. GIAPREZA alone represents roughly $72M in FY 2025 revenue; any formulary challenge or competitor entry in vasopressors would be immediately felt.

Calibration: moderate probability. The recent growth track record (3 consecutive quarters of >50% U.S. growth) suggests execution is improving, but the organization is still young.

3. Concentrated Investment Portfolio Risk - Armata Pharmaceuticals

The mechanism: Innoviva holds approximately $397.9 million in Armata Pharmaceuticals equity as of December 31, 2025. Armata is a clinical-stage bacteriophage company. If Phase 3 data for Armata's lead program fails, or if bacteriophage therapy fails to achieve regulatory approval, this holding could be impaired substantially. Armata's share price has already shown significant volatility - in Q3 2024, a $35.2 million unfavorable fair value adjustment on equity investments caused net income to fall from $82M (Q3 2023) to just $1.2M. The fair value swings in this investment can dwarf the operating earnings of the entire business.

Innoviva's Q3 2024 net income was $1.2M (basic EPS $0.02), down from $82.0M in Q3 2023, primarily due to a $35.2M unfavorable fair value adjustment on equity investments, primarily Armata Pharmaceuticals.

This is a concentrated, illiquid, binary-outcome risk. If Armata's clinical program succeeds, this is a multi-hundred-million-dollar gain. If it fails, the loss is comparable in magnitude. This investment introduces significant volatility into Innoviva's reported financials.

Calibration: moderate-to-high probability of meaningful volatility; binary outcome.

4. NUZOLVENCE Commercialization Uncertainty

The mechanism: NUZOLVENCE was approved in December 2025, but Innoviva has not yet decided whether to commercialize it independently or through a partner. The product targets a largely outpatient STI market (clinics, urgent care, public health) that is categorically different from IST's ICU/hospital focus. Building or contracting a separate commercialization infrastructure is expensive. Competing against gepotidacin (approved simultaneously, marketed by GSK - which has a very large commercial infrastructure) without a large-pharma partner puts NUZOLVENCE at a structural disadvantage in reaching the broad prescriber base needed for a high-volume STI drug.

If Innoviva cannot find a strong commercialization partner on acceptable terms, or if it attempts to commercialize independently and under-invests, NUZOLVENCE could significantly underperform its clinical potential. The commercial window is also potentially limited - vaccine-based gonorrhea prevention (UK launched a program in August 2025) could eventually reduce the patient pool, though this is a very long-term consideration.

Calibration: moderate probability of commercial underperformance; manageable if handled strategically.

5. Antibiotic Stewardship and Volume Constraints

The mechanism: High-value antibiotics like XACDURO are deliberately restricted by hospital stewardship programs. Infectious disease programs recommend that XACDURO be reserved for confirmed XDR Acinetobacter infections - which is clinically correct but limits volume. As XACDURO grows, it may begin hitting the ceiling of the addressable patient population (HABP/VABP caused by Acinetobacter is by definition a niche). The global Acinetobacter pneumonia market is estimated at $300-700 million - this is not a blockbuster market. XACDURO's path to sustained growth eventually depends on label expansion or geographic expansion.

Calibration: low probability near-term, higher medium-term.

6. Generic Competition for GIAPREZA

The mechanism: GIAPREZA's chemical patent (angiotensin II synthesis) eventually expires. Generic companies could develop bioequivalent angiotensin II products and significantly undercut GIAPREZA's pricing. The drug's clinical moat is modest - any generic angiotensin II IV formulation with equivalent bioequivalence data would be interchangeable in a formulary context. GIAPREZA is currently the largest IST product. Patent expiry timing and any challenges from generic filers are a material risk to the IST segment.

Calibration: moderate probability over a 5-7 year horizon.

Section 9: Walk the Talk

Tracking Innoviva management's commitments across four earnings periods tells a coherent story of consistent delivery with one meaningful structural caveat.

Q3 2024 - The Setup

In the Q3 2024 report (November 6, 2024), CEO Pavel Raifeld described the business as being in its "second year of operation" for IST, emphasizing "consistent sales expansion." He previewed two major events expected to occur in 2025: an NDA submission for zoliflodacin (targeted for early 2025) and the launch of ZEVTERA (following the anticipated execution of the Basilea licensing agreement). Both were forward-looking statements that could be tracked.

The royalty segment was described as stable. At the time of Q3 2024, the net income figure was severely impacted by fair value adjustments on Armata - management addressed this by noting it was mark-to-market accounting, not cash. This was accurate and honest disclosure.

Q4/FY 2024 - The Guidance Year

At the Q4/FY 2024 call (February 26, 2025), management made three trackable commitments:

IST U.S. net product sales to exceed $100M in FY 2025.
NDA filing for zoliflodacin targeted for H1 2025.
ZEVTERA U.S. commercial launch in mid-2025.

"We anticipate U.S. net product sales to exceed $100 million in 2025."

All three were delivered. The NDA was filed; the FDA approved zoliflodacin (as NUZOLVENCE) in December 2025. ZEVTERA launched in May 2025. IST U.S. net product sales came in at $119.2 million for FY 2025 - 19% above the floor guidance.

XACDURO's addition to the 2024 IDSA guidelines was also flagged as a commercial catalyst. This was delivered and management cited the guidelines inclusion as a driver of accelerating XACDURO prescriptions.

Q1 2025 - Consistency Under Pressure

Q1 2025 (May 7, 2025) was notable because Innoviva reported a net loss of $46.6 million despite strong operating performance, due to fair value adjustments on the investment portfolio. Management held the line:

"[The company maintains] robust cash flows from its GSK royalties portfolio... [and] a strong balance sheet."

The framing was disciplined - operating performance was strong (IST U.S. sales up 52% YoY), the balance sheet was healthy ($319M cash), and the net loss was a mark-to-market accounting artifact. Raifeld did not spin the net loss but contextualized it accurately. The zoliflodacin NDA filing guidance was repeated (H1 2025). ZEVTERA launch was maintained (mid-2025). No backtracking.

Q3 2025 - Delivery Confirmation

By Q3 2025 (November 5, 2025), the deliveries were stacking up. ZEVTERA had launched. IST had now delivered three consecutive quarters of >50% U.S. revenue growth. The zoliflodacin PDUFA date was confirmed as December 15, 2025. The $125M share repurchase was announced - a capital allocation signal from a management team confident in its trajectory. Armata's positive Phase 2 data drove favorable fair value movements that contributed to $89.9M net income for the quarter.

Assessment

This management team does what it says. The commitments made in the Q4 2024 call - three specific, trackable things - were all delivered on time. The royalty guidance (stable) was accurate. The IST growth guidance was beaten. The pipeline milestone (zoliflodacin approval) was achieved within the communicated timeline. No guidance was quietly dropped or revised downward.

The structural caveat is the volatility of reported net income due to investment fair value swings. Management is transparent about this being mark-to-market accounting, and net cash and operating performance have been consistently strong. But the headline EPS can swing wildly quarter to quarter, which could mislead observers who read only the bottom line. The net loss of $46.6 million in Q1 2025 followed by $89.9 million net income in Q3 2025 is not a sign of operational volatility - it is the accounting treatment of a large equity portfolio. Management has consistently and correctly explained this. Credit for intellectual honesty.

The one area to watch: the decision on NUZOLVENCE commercialization. Management has said H2 2026 but has not committed to an approach (own vs. partner). This is still an open question and the key unresolved execution challenge going into 2026.

Section 10: Scenarios

Bull Case

The royalty stream stabilizes rather than declines. BREO and ANORO hold their prescriber base better than feared as COPD physicians, particularly in community practice, resist the formulary friction of switching to TRELEGY. Meanwhile, ZEVTERA builds traction as the definitive MRSA bacteremia therapy - the fact that it is a cephalosporin (a familiar, trusted drug class) with MRSA activity becomes a compelling story for formulary committees, and it begins generating meaningful quarterly contributions by H2 2026. XACDURO, now in IDSA guidelines, earns deeper penetration into academic medical centers and teaching hospitals as Acinetobacter cases rise due to global AMR trends. GIAPREZA crosses $100 million in annualized sales as ICUs nationwide standardize it into septic shock protocols.

NUZOLVENCE finds a strong commercialization partner - perhaps a large public health-focused company or an international pharma with STI market experience - who can drive volume rapidly given the global urgency of ceftriaxone-resistant gonorrhea. The gonorrhea market proves larger than expected as testing rates improve and surveillance-driven treatment protocols expand.

Armata Pharmaceuticals succeeds in Phase 3 for Staphylococcus aureus bacteremia with its bacteriophage platform. FDA approval of a commercial bacteriophage product would be a historic regulatory milestone and would potentially allow Innoviva to realize its nearly $400 million Armata position at a substantial premium to book. The investment portfolio compounds the business in a way the royalties alone never could.

In this world, IST surpasses its $150M 2026 guidance and the business becomes primarily valued on its antibiotic commercial platform - a true specialty pharma company, not a royalty vehicle.

Base Case

The royalties business continues its gradual, predictable decline - perhaps 3-5% per year as TRELEGY slowly displaces BREO/ANORO in the COPD market. This is tolerable because IST continues growing at double-digit rates, and the combination of $200-250M in royalties plus an expanding product business keeps total revenue growing in the low double digits annually. GIAPREZA grows modestly, XACDURO maintains high-growth momentum as Acinetobacter infections and MDR awareness expand, and ZEVTERA takes 12-18 months to build meaningful quarterly revenue as the MRSA bacteremia indication establishes in formularies.

NUZOLVENCE is commercialized in H2 2026 with a co-promotion partner, contributing modestly in its first year. The Armata position sees continued clinical progress without a definitive Phase 3 readout in the near term - the position stays marked near current levels.

Management delivers on the $150M+ 2026 IST guidance. The share repurchase program continues, providing per-share earnings support. The balance sheet stays healthy - $500M+ in cash supports both commercial investment and opportunistic healthcare investments.

Bear Case

The royalties erode faster than expected - perhaps 8-10% annually as TRELEGY captures increasingly dominant market share and GSK's promotional spend shifts aggressively toward the triple combination. By 2028, annual royalties have declined meaningfully, narrowing the cash cushion that has funded IST's build.

Simultaneously, IST hits commercial friction. GIAPREZA's patent landscape draws a generic filer - a Para IV challenge or equivalent - that creates uncertainty and pricing pressure just as GIAPREZA is becoming the largest product. ZEVTERA struggles to penetrate formularies because MRSA bacteremia is a smaller market than hoped and the clinical differentiation vs. daptomycin is not compelling enough to justify the formulary effort at cost-constrained hospital systems.

The Armata Pharmaceuticals position reverses on Phase 3 disappointment in bacteremia. A $200-300 million fair value impairment hits Innoviva's balance sheet in a single quarter, destroying reported earnings and forcing a reevaluation of the investment portfolio strategy. The company holds significant equity in other early-stage companies (Gate Neurosciences, Beacon Biosignals, Lyndra) that are pre-revenue and could face further impairments.

NUZOLVENCE struggles commercially - Innoviva cannot find a partner on acceptable economic terms, attempts to commercialize independently with its hospital-focused sales force (which has no STI market relationships), and NUZOLVENCE cedes market share to gepotidacin which benefits from GSK's enormous commercial infrastructure. The gonorrhea product fails to add meaningful revenue in its first two years on market.

In this scenario, Innoviva's three-pillar strategy - royalties funding IST funding investments - loses its reinforcing logic. Declining royalties no longer comfortably fund commercial spending, IST growth disappoints, and the investment portfolio produces losses rather than gains. The business does not fail - the royalty stream still generates substantial cash - but the growth narrative collapses and the business reverts to being valued as a declining royalty vehicle with a speculative drug company attached.

Sources: